New treatment options for colorectal cancer

New England Journal of Medicine

Volumn 351, Issue 4, 2004, Pages 391-392

  Erlichman, Charles ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; GEFITINIB; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIMERIZATION; DRUG EFFICACY; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RASH; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; EXANTHEMA; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN;

EID: 3242703033     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048151     Document Type: Editorial

References (14)

1. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment J Natl Cancer Inst 2003; 95:851-67.
2. Thomas SM, Grandis JR, Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004;30:255-68.
3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14.
4. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7, [Erratum, Lancet 2000;355:1372.]
5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7, [Erratum, Lancet 2000;355:1372.]
6. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hiklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
8. Cunningham D, Humblet Y, Siena S, et al. A randomised comparison of cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
9. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
11. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-9.
12. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Prog Proc Am Soc Clin Oncol 2001;20:3a. abstract.
13. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
14. Randal J. Erbitux trial flawed from the beginning, committee finds. J Natl Cancer Inst 2002;94:1824-5.